Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 26Withdrawn 3Terminated 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Recurrence 1Malignant Neoplasms of Digestive Organs 1Advanced Nonhematologic Malignancies 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × MLN 8237 × Clear all
NCT02780011 2018-07-27

AD3LE

The Methodist Hospital Research Institute

Phase 1 Withdrawn

Recurrence

NCT02812056 2017-03-27

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Other neoplasm

Malignant Neoplasms of Digestive Organs

NCT01613261 2013-11-01

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Withdrawn

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡